CAMBRIDGE, England--(BUSINESS WIRE)--Mar 17, 2026--
Alchemab Therapeutics has appointed Ulrich Wendt, PhD MBA, as Chief Business Officer (CBO) to expand partnerships with biopharma for the development of novel antibody therapeutics. As a proven dealmaker and strategist, Dr Wendt brings more than a decade of experience in delivering high-value partnerships across all pipeline stages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317585022/en/
Before joining Alchemab, he served as Global Head of Business Development Immunology at Sanofi. Prior to this, Dr Wendt drove global Business Development for Sanofi’s diabetes and primary care business units, and oversaw global search & evaluation and alliance management teams in cardiometabolic disease.
His appointment builds on Alchemab’s recent pharma licensing deals, Series A funding extension, and progression of their first asset into clinical trials.
“As CBO, Ulrich will lead Alchemab's business development and alliance management, working closely with the executive team to expand the company’s partnerships across biopharma and adjacent sectors,” said Jane Osbourn, CEO and Co-Founder of Alchemab. “He will also help guide our corporate strategy as we continue scaling our AI-enabled platform capabilities.”
With academic roots in biostructure and biophysics, Dr Wendt earned his PhD from Freiburg University, completed postdoctoral training at UC Berkeley and Genentech, and gained an MBA from IMD, Lausanne.
"Alchemab's discovery platform positions the company at the intersection of experimental and AI-enabled discovery," Dr Wendt said. "Within the last two years the company has advanced into clinical trials and delivered a stream of preclinical candidates with novel target biology. I am excited to be joining Jane and the Alchemab team at this pivotal time to help position the company for the next wave of growth."
Alchemab is a biotechnology company uncovering the immune secrets of disease-resilient individuals to discover and develop novel antibody therapeutics. Their first asset entered clinical trials in 2025 as part of a licensing deal with Lilly.
The company’s platform integrates the world's largest antibody database derived from disease-resilient individuals with a proprietary AI-powered antibody search engine designed to identify the antibodies that protect them. By pioneering this approach, Alchemab has generated a broad pipeline of treatments for hard-to-treat diseases that could not have been discovered with traditional methods.
For more information, visit alchemab.com
Dr Ulrich Wendt has been appointed Chief Business Officer at Alchemab Therapeutics
AMSTERDAM--(BUSINESS WIRE)--Mar 17, 2026--
autobiz, one of Europe’s leading providers of automotive market data and residual values, contributes more than 20 years of experience across 22 European markets. Its valuation models are based on daily market observations and follow IFRS compliant and audited methodologies designed to ensure stability, transparency, and consistency over time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317726493/en/
BearingPoint complements this expertise with its Asset & Funding platform, developed for Asset-Backed Securities (ABS) and other asset-based funding instruments. The platform supports financial institutions across the full lifecycle of asset-based financing transactions, from data integration and portfolio structuring to cashflow and scenario simulations, as well as reporting, monitoring, and regulatory transparency.
Through this partnership, autobiz’s residual value data and forward-looking value forecasts are integrated into BearingPoint’s platform, enabling financial institutions to rely on market-based, regularly reviewed residual values when structuring and monitoring their automotive financing programs.
What this partnership brings to financial institutions
By combining independent automotive data expertise with asset-based funding capabilities, clients can benefit from:
The result is a more robust and sustainable asset-based funding process in a market environment characterized by volatility and increased scrutiny.
Responding to evolving market expectations
In recent years, used-car markets have experienced increased volatility, while regulatory and investor expectations around data quality and transparency have intensified. Financial institutions are therefore seeking stronger foundations for their residual value assumptions and risk management when structuring portfolios for asset-based funding initiatives.
The collaboration between BearingPoint and autobiz directly addresses these challenges by combining deep automotive market knowledge with structured finance expertise across the entire financing lifecycle.
A shared ambition: strengthening transparency in asset based automotive funding
“This partnership reflects our ambition to extend the value of our automotive market expertise into the financial structuring sphere. By working with BearingPoint, we enable financial institutions to integrate reliable, market-based residual values into their funding processes, contributing to greater transparency and long-term stability across Europe,” says Bertrand Chataing, Chief Sales and Development Director at autobiz.
“By embedding autobiz’s residual value intelligence into BearingPoint’s Asset & Funding platform, our partnership turns high quality automotive market data into actionable asset-based funding decisions. It creates value for Vehicle and Equipment as a Service models by enabling consistent pricing, lifecycle management, and funding decisions across operational and financial processes thus strengthening transparency, capital efficiency, and resilience across the full asset horizon,“ says Donald Wachs, Partner and Global Leader BearingPoint Products.
About autobiz
Since 2004, autobiz has been supporting European automotive players with trade-in and used-car data solutions. Its 280 employees continuously build on more than 20 years of used-car data history combined with strong web, software, and automotive operational expertise. autobiz operates offices in Paris, Berlin, Valencia, and Milan and serves more than 20 leading players in the used-car market as well as around 6,500 points of sale across 22 European countries.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. We help businesses transform by combining deep industry expertise with strong capabilities in strategy, operations, and technology. Dedicated SAP and Microsoft transformation units, a strong focus on AI, and outcome-based products enable us to provide tailored, innovative solutions that create measurable and sustainable value.
In addition to our core consulting operations, we run two joint ventures. Arcwide, our joint venture with IFS, specializes in business transformation enabled by IFS technology. BearingPoint North America, our joint venture with ABeam Consulting, focuses on consulting excellence and business transformation built on SAP.
BearingPoint works with many of the world’s leading companies and public-sector organizations. Together with its strategic alliance partner ABeam Consulting, the firm brings together more than 15,000 professionals and serves clients in over 70 countries, delivering seamless business transformation, strengthening performance, and driving sustainable impact.
BearingPoint is recognized among TIME World’s Best Companies and Forbes World’s Best Employers. The firm is also a certified B Corporation, committed to responsible business and creating long-term value for organizations, people, and society.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Two leading European companies announce a partnership aimed at residual value management in the context of asset-based funding for banks, captives, and leasing companies across Europe.
